Mounjaro®
Starting from £179.99/mo
Start journey Learn moreLosing a stone in a single month on Mounjaro is possible for some people, particularly in the early weeks of treatment, but it is not the norm — and the decision about whether a result like that is realistic for you depends on several factors your prescriber will weigh up. Mounjaro (tirzepatide) is a prescription-only medicine licensed for weight management in the UK. A clinician must assess your suitability before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common misconception about Mounjaro is that it works like a tap you turn on and weight floods out at a steady, predictable rate. It doesn't work that way. What actually happens is that your appetite drops substantially, often within the first week or two, so your calorie intake falls without the constant effort of willpower. Combine that with some reduction in water retention in the early weeks, and a heavier person starting treatment can plausibly lose 10–14lb in a first month. That said, the 2.5mg starting dose is a tolerability step, its job is to let your body adjust, not to deliver the full appetite-suppressing effect. People who lose a stone in month one are usually those with a higher starting weight, where the relative calorie deficit is larger, and sometimes those who make meaningful dietary changes alongside treatment.
The SURMOUNT-1 clinical trial, published in the New England Journal of Medicine, tracked 2,539 adults over 72 weeks. Average weight loss at the 15mg dose was around 20–21%. That averages out to roughly 4–6% of body weight in the first 12 weeks for many participants, meaningful, but spread over three months, not one.
If a stone in a month is the target, it helps to ask a different question: what does realistic look like for my starting point? Our page on losing a stone on Mounjaro goes into the fuller picture of timelines and what influences them.
Starting weight matters more than most people expect. Someone who weighs 18 stone has a larger absolute calorie surplus to cut than someone who weighs 12 stone, so the same dose tends to produce a larger number on the scales in the early months. This is normal biology, not a flaw in the medicine.
Dose stage plays a real role too. Prescribers titrate Mounjaro upward through 2.5mg, 5mg, 7.5mg and beyond, and our tirzepatide guide describes the licensed strengths and what the dose-increase schedule looks like. The higher the maintenance dose you reach, the stronger the appetite suppression tends to be. Month one is almost always at the lowest strength.
What you eat and how active you are still matter. The licence is for use alongside a reduced-calorie diet and increased physical activity. Mounjaro reduces hunger, but it doesn't choose your meals. People who use the reduced appetite as an opportunity to improve food quality (more protein, adequate fibre, good hydration) tend to sustain better results over time. Details on how to think about food alongside treatment are worth raising at your first review. Our overview of what to expect in your first month on Mounjaro covers what that period typically looks like, and if you want a closer look at the numbers and changes people commonly see, our dedicated page on one month on Mounjaro walks through the experience in more detail.
Individual variation in how quickly someone absorbs and responds to the medicine is real and not fully predictable in advance. Some people are more responsive; some need a higher dose before the effect is pronounced. A prescriber assesses your whole picture (not just your BMI) before deciding on the right starting point and how to monitor progress.
If you're deciding whether to start Mounjaro, framing the goal as "a stone in a month" can set you up for disappointment in a way that doesn't serve you. The more useful frame is: am I likely to lose meaningful, sustained weight over three to six months, and is Mounjaro the right clinical route to get there?
The trial data says yes for most eligible people, weight loss in the SURMOUNT programme, involving thousands of adults, was consistent and clinically significant. Faster early loss is common. But the months from three to twelve often produce more total weight lost than the dramatic first four weeks, precisely because the dose is still increasing and the habit changes are compounding. If you want to understand what's possible over a longer horizon, reading about losing 3 stone on Mounjaro gives a useful real-world perspective on what that kind of progress involves. There's also a useful comparison of what different amounts of weight loss look like on the timeline on our two-stone Mounjaro page, if you want a longer-horizon view.
It's also worth knowing that starting a free consultation with our prescribers is where the honest conversation about your personal trajectory begins. NICE guidance (TA1026) recommends reviewing whether treatment is continuing to benefit you; your prescriber tracks this from the start, not just at a six-month checkpoint.
One practical note: if you experience significant gastrointestinal side effects in the first weeks (nausea is the most common) they tend to settle as your body adjusts, and they don't usually prevent weight loss from occurring. Severe or persistent symptoms are a reason to contact your prescriber, not to push through alone. Our clinical FAQs cover what to do if you have concerns during treatment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.